<p>该整合旨在通过生物特征信号为数百万用户提供对偏头痛诱因的更深入洞察。</p>
<p>伊利诺伊州水晶湖 --（商业资讯）--Aptar Digital Health，AptarGroup, Inc.（纽约证券交易所代码：ATR）的一部分，是全球药物和消费品计量、分配和保护技术的领导者，今天宣布与ŌURA 建立合作伙伴关系，将 Aptar 的 Migraine Buddy®与 Oura Ring 整合。Migraine Buddy 是一款拥有数百万用户的领先偏头痛追踪应用，将与 Oura Ring 的连续生物特征数据连接，旨在为个人提供关于其偏头痛模式和潜在诱因的个性化洞察。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20260106263818/en/2683737/4/MB_x_Oura_Ring_PR.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20260106263818/en/2683737/4/MB_x_Oura_Ring_PR.jpg"/></p>
<p>Aptar Digital Health 与ŌURA 合作，通过将 Migraine Buddy®与 Oura Ring 连接，推动偏头痛洞察的进步</p>
<p>Migraine Buddy 旨在通过数据驱动的洞察力赋能头痛和偏头痛患者。其用户友好的设计和强大的追踪能力迅速获得了广泛的欢迎，成为首选的移动应用。通过将 Migraine Buddy 的详细症状追踪、报告和指导能力与 Oura Ring 的连续生物特征数据（包括睡眠、心率变异性、温度趋势、周期洞察等）整合，用户可能能够获得对潜在偏头痛诱因和相关生理模式的可见性。</p>
<p>虽然该综合解决方案旨在服务所有人，但对女性尤其有价值，因为女性由于荷尔蒙波动而更频繁地经历偏头痛。由于大多数 Migraine Buddy 用户为女性，能够将 Oura Ring 与偏头痛数据连接，可能有助于揭示荷尔蒙变化如何影响症状，并支持对整体健康的更深入理解。</p>
<p>偏头痛是一种神经系统疾病，特征是反复出现中度至重度强度的头痛，常伴有恶心、对光敏感和其他症状。它影响全球约 12% 的人口，女性由于荷尔蒙因素受到的不成比例影响。根据世界卫生组织的数据，偏头痛导致高水平的人口残疾和健康问题。</p>
<p>“这项合作旨在为我们的用户提供无缝且完全自动化的追踪工具，以更深入地理解可能影响他们偏头痛发作的因素，” Aptar Digital Health 首席商务官 Aurore Beaume 表示。“将我们的洞察结合在一起，旨在创造一个更全面的体验，帮助人们识别模式并做出选择以改善他们的健康。”</p>
<p>“我们与ŌURA 的合作反映了 Aptar 推动整个从配方到患者的创新承诺，” Aptar Pharma 总裁 Gael Touya 表示。“将 Migraine Buddy 与 Oura Ring 连接，使 Aptar Pharma 更接近未来健康管理的愿景，在这个愿景中，数据赋能每位患者预见和更好地管理他们的状况。”</p>
<p>“在ŌURA，我们致力于确保连续的生物特征洞察在帮助人们理解和管理健康方面发挥重要作用，”ŌURA 首席商业官 Dorothy Kilroy 表示。“这对于女性尤其如此，因为她们的经历——包括偏头痛——往往受到荷尔蒙变化的影响。作为一家深度投资于女性健康的公司，我们与 Aptar Digital Health 的合作建立在这一使命之上，将 Oura 的实时信号与 Migraine Buddy 的丰富追踪体验结合在一起，为个人提供更清晰、更具可操作性的偏头痛模式视图。这是朝着一个偏头痛护理更加主动、基于每个人独特生理特征的未来迈出的重要一步。”</p>
<p><strong>关于 Aptar</strong></p>
<p>Aptar 是全球药物和消费品计量、分配和保护技术的领导者。Aptar 服务于多个有吸引力的终端市场，包括制药、美容、食品、饮料、个人护理和家庭护理。Aptar Digital Health 创建端到端解决方案，以提升患者的日常体验，利用数字干预的整体生态系统。通过行业领先的产品和解决方案组合，Aptar Digital Health 的产品结合了移动和网络应用、连接药物递送系统、入职、培训和先进的数据分析服务，积极赋能患者并创造积极的治疗旅程。Aptar 总部位于伊利诺伊州水晶湖，在 20 个国家拥有超过 13,000 名专注的员工。欲了解更多信息，请访问 www.aptardigitalhealth.com 和 www.aptar.com。</p>
<p>本新闻稿包含前瞻性声明，包括关于 Migraine Buddy 与 Oura Ring 计划整合的内容，以及该整合对用户的预期好处和结果。前瞻性声明通常可以通过它们不严格与历史或当前事实相关联的事实以及使用 “预计”、“预期”、“相信”、“估计”、“未来”、“潜在”、“持续” 等词语或未来或条件动词如 “将”、“应该”、“会” 和 “可能” 来识别。这些前瞻性声明是根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条的安全港条款作出的，并基于我们的信念以及我们当前可获得的信息和假设。因此，由于我们运营和商业环境中存在的已知或未知的风险和不确定性，我们的实际结果或其他事件可能与这些前瞻性声明中所表达或暗示的内容有实质性差异，包括但不限于：Migraine Buddy 与 Oura Ring 的成功整合；我们向用户提供有意义的生物识别驱动的洞察的能力；监管要求和合规性；以及竞争，包括技术进步。有关这些及其他风险和不确定性的更多信息，请参见我们向证券交易委员会提交的文件，包括我们 10-K 表格和 10-Q 表格中 “风险因素” 和 “管理层对财务状况和经营成果的讨论与分析” 下的讨论。我们没有义务公开更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，法律要求的情况除外。</p>
<p>Oura Ring 不是医疗设备，不用于诊断、治疗、治愈、监测或预防医疗状况或疾病。</p>
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1Burch RC, Buse DC, Lipton RB. 偏头痛：流行病学、负担和共病。神经病学临床。2019 年 11 月；37(4)：631-649。doi: 10.1016/j.ncl.2019.06.001。2019 年 8 月 27 日在线发表。PMID: 31563224.</td>
</tr>
<tr>
<td>2 https://www.who.int/news-room/fact-sheets/detail/headache-disorders</td>
</tr>
</tbody>
</table>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAxMDYyNjM4MThyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAxMDYyNjM4MThyMQ"/></p>
<p>查看在 businesswire.com 上的源版本：https://www.businesswire.com/news/home/20260106263818/en/</p>
<p><strong>Aptar 投资者关系联系人：</strong></p>
<p>Mary Skafidas</p>
<p>mary.skafidas@aptar.com</p>
<p>+1 347 351 6407</p>
<p><strong>Aptar 制药媒体联系人：</strong></p>
<p>Carolyn Penot</p>
<p>carolyn.penot@aptar.com</p>
<p>+33 6 37 36 76 84</p>
<p><strong>Aptar 媒体联系人：</strong></p>
<p>Katie Reardon</p>
<p>katie.reardon@aptar.com</p>
<p>+1 815 479 5671</p>
<p>来源：AptarGroup, Inc.</p>

阿普达

<p>Aptar Digital Health 与 ŌURA 合作，将其 Migraine Buddy 应用程序与 Oura Ring 整合，旨在通过生物数据为用户提供个性化的偏头痛触发因素洞察。这一合作旨在增强个人，特别是女性，对偏头痛模式和潜在触发因素的理解。该整合将 Migraine Buddy 的详细症状追踪与 Oura Ring 的持续生物数据相结合，促进对偏头痛管理的主动应对。Aptar 强调通过这一合作伙伴关系对健康管理创新的承诺</p>

<p><em>The integration aims to empower millions of users with deeper insights into migraine triggers through biometric signals.</em></p>
<div class="lb-trans"><p>该整合旨在通过生物特征信号为数百万用户提供对偏头痛诱因的更深入洞察。</p>
</div><p>CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Digital Health, part of AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced a partnership with ŌURA to integrate Aptar’s Migraine Buddy® with Oura Ring. Migraine Buddy, a leading migraine tracking app with millions of users, will connect with the continuous biometric data from Oura Ring, with the goal of providing individuals with personalized insights into their migraine patterns and potential triggers.</p>
<div class="lb-trans"><p>伊利诺伊州水晶湖 --（商业资讯）--Aptar Digital Health，AptarGroup, Inc.（纽约证券交易所代码：ATR）的一部分，是全球药物和消费品计量、分配和保护技术的领导者，今天宣布与ŌURA 建立合作伙伴关系，将 Aptar 的 Migraine Buddy®与 Oura Ring 整合。Migraine Buddy 是一款拥有数百万用户的领先偏头痛追踪应用，将与 Oura Ring 的连续生物特征数据连接，旨在为个人提供关于其偏头痛模式和潜在诱因的个性化洞察。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20260106263818/en/2683737/4/MB_x_Oura_Ring_PR.jpg" alt="" original-src="https://mms.businesswire.com/media/20260106263818/en/2683737/4/MB_x_Oura_Ring_PR.jpg"/></p>
<p>Aptar Digital Health and ŌURA Collaborate to Advance Migraine Insights by Connecting Migraine Buddy® with Oura Ring</p>
<div class="lb-trans"><p>Aptar Digital Health 与ŌURA 合作，通过将 Migraine Buddy®与 Oura Ring 连接，推动偏头痛洞察的进步</p>
</div><p>Migraine Buddy is designed to empower people suffering from headaches and migraine through data-driven insights. Its user-friendly design and robust tracking capabilities have quickly garnered widespread popularity, making it a top-choice mobile application. By integrating Migraine Buddy’s detailed symptom tracking, reporting, and coaching capabilities, with continuous biometric data from Oura Ring, including sleep, heart rate variability, temperature trends, cycle insights, and more, users may be able to gain visibility into potential migraine triggers and related physiological patterns.</p>
<div class="lb-trans"><p>Migraine Buddy 旨在通过数据驱动的洞察力赋能头痛和偏头痛患者。其用户友好的设计和强大的追踪能力迅速获得了广泛的欢迎，成为首选的移动应用。通过将 Migraine Buddy 的详细症状追踪、报告和指导能力与 Oura Ring 的连续生物特征数据（包括睡眠、心率变异性、温度趋势、周期洞察等）整合，用户可能能够获得对潜在偏头痛诱因和相关生理模式的可见性。</p>
</div><p>While the combined solution is designed for everyone, it is especially valuable for women, who experience migraines more frequently due to hormonal fluctuations. With the majority of Migraine Buddy users being women, the ability to connect Oura Ring to migraine data may help enlighten how hormonal shifts influence symptoms and support a deeper understanding of overall health.</p>
<div class="lb-trans"><p>虽然该综合解决方案旨在服务所有人，但对女性尤其有价值，因为女性由于荷尔蒙波动而更频繁地经历偏头痛。由于大多数 Migraine Buddy 用户为女性，能够将 Oura Ring 与偏头痛数据连接，可能有助于揭示荷尔蒙变化如何影响症状，并支持对整体健康的更深入理解。</p>
</div><p>Migraine is a neurological disorder characterized by recurring headaches of moderate to severe intensity, often accompanied by nausea, sensitivity to light, and other symptoms. It affects approximately 12% of the global population1, disproportionately impacting women due to hormonal factors. According to the World Health Organization, migraines are responsible for high population levels of disability and ill health2.</p>
<div class="lb-trans"><p>偏头痛是一种神经系统疾病，特征是反复出现中度至重度强度的头痛，常伴有恶心、对光敏感和其他症状。它影响全球约 12% 的人口，女性由于荷尔蒙因素受到的不成比例影响。根据世界卫生组织的数据，偏头痛导致高水平的人口残疾和健康问题。</p>
</div><p>“This partnership is about empowering our users with seamless and fully automated tracking tools to more deeply understand what could impact their migraine episodes,” said Aurore Beaume, Chief Business Officer, Aptar Digital Health. “Bringing our insights together aims to create an even more holistic experience that can help people recognize patterns and make choices to enhance their health.”</p>
<div class="lb-trans"><p>“这项合作旨在为我们的用户提供无缝且完全自动化的追踪工具，以更深入地理解可能影响他们偏头痛发作的因素，” Aptar Digital Health 首席商务官 Aurore Beaume 表示。“将我们的洞察结合在一起，旨在创造一个更全面的体验，帮助人们识别模式并做出选择以改善他们的健康。”</p>
</div><p>“Our collaboration with ŌURA reflects Aptar’s commitment to drive innovation across the entire journey from formulation to patients,” said Gael Touya, President, Aptar Pharma. “Connecting Migraine Buddy with Oura Ring brings Aptar Pharma closer to the future management of health where data empowers every patient to anticipate and better manage their conditions.”</p>
<div class="lb-trans"><p>“我们与ŌURA 的合作反映了 Aptar 推动整个从配方到患者的创新承诺，” Aptar Pharma 总裁 Gael Touya 表示。“将 Migraine Buddy 与 Oura Ring 连接，使 Aptar Pharma 更接近未来健康管理的愿景，在这个愿景中，数据赋能每位患者预见和更好地管理他们的状况。”</p>
</div><p>“At ŌURA, we’re committed to ensuring that continuous biometric insights play a meaningful role in how people understand and manage their health,” said Dorothy Kilroy, Chief Commercial Officer at ŌURA. “This is especially true for women, whose experiences—including migraines—are often shaped by hormonal shifts. As a company deeply invested in advancing women’s health, our partnership with Aptar Digital Health builds on that mission, bringing together Oura’s real-time signals with Migraine Buddy’s rich tracking experience to give individuals a clearer, more actionable view of their migraine patterns. It’s a powerful step toward a future where migraine care is more proactive and grounded in each person’s unique physiology.”</p>
<div class="lb-trans"><p>“在ŌURA，我们致力于确保连续的生物特征洞察在帮助人们理解和管理健康方面发挥重要作用，”ŌURA 首席商业官 Dorothy Kilroy 表示。“这对于女性尤其如此，因为她们的经历——包括偏头痛——往往受到荷尔蒙变化的影响。作为一家深度投资于女性健康的公司，我们与 Aptar Digital Health 的合作建立在这一使命之上，将 Oura 的实时信号与 Migraine Buddy 的丰富追踪体验结合在一起，为个人提供更清晰、更具可操作性的偏头痛模式视图。这是朝着一个偏头痛护理更加主动、基于每个人独特生理特征的未来迈出的重要一步。”</p>
</div><p><strong>About Aptar</strong></p>
<div class="lb-trans"><p><strong>关于 Aptar</strong></p>
</div><p>Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Aptar Digital Health creates end-to-end solutions to enhance patient experiences every day, leveraging a holistic ecosystem of digital interventions. Amplified by an industry-leading portfolio of products and solutions, Aptar Digital Health’s offering combines mobile and web apps, connected drug delivery systems, onboarding, training and advanced data analytics services to actively empower patients and create a positive treatment journey. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, please visit www.aptardigitalhealth.com and www.aptar.com.</p>
<div class="lb-trans"><p>Aptar 是全球药物和消费品计量、分配和保护技术的领导者。Aptar 服务于多个有吸引力的终端市场，包括制药、美容、食品、饮料、个人护理和家庭护理。Aptar Digital Health 创建端到端解决方案，以提升患者的日常体验，利用数字干预的整体生态系统。通过行业领先的产品和解决方案组合，Aptar Digital Health 的产品结合了移动和网络应用、连接药物递送系统、入职、培训和先进的数据分析服务，积极赋能患者并创造积极的治疗旅程。Aptar 总部位于伊利诺伊州水晶湖，在 20 个国家拥有超过 13,000 名专注的员工。欲了解更多信息，请访问 www.aptardigitalhealth.com 和 www.aptar.com。</p>
</div><p><em>This press release contains forward-looking statements, including regarding the planned integration of Migraine Buddy with Oura Ring and the anticipated benefits and outcomes of that integration for users. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by use of words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of the Migraine Buddy and Oura Ring; our ability to deliver meaningful biometric-driven insights to users; regulatory requirements and compliance; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</em></p>
<div class="lb-trans"><p>本新闻稿包含前瞻性声明，包括关于 Migraine Buddy 与 Oura Ring 计划整合的内容，以及该整合对用户的预期好处和结果。前瞻性声明通常可以通过它们不严格与历史或当前事实相关联的事实以及使用 “预计”、“预期”、“相信”、“估计”、“未来”、“潜在”、“持续” 等词语或未来或条件动词如 “将”、“应该”、“会” 和 “可能” 来识别。这些前瞻性声明是根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条的安全港条款作出的，并基于我们的信念以及我们当前可获得的信息和假设。因此，由于我们运营和商业环境中存在的已知或未知的风险和不确定性，我们的实际结果或其他事件可能与这些前瞻性声明中所表达或暗示的内容有实质性差异，包括但不限于：Migraine Buddy 与 Oura Ring 的成功整合；我们向用户提供有意义的生物识别驱动的洞察的能力；监管要求和合规性；以及竞争，包括技术进步。有关这些及其他风险和不确定性的更多信息，请参见我们向证券交易委员会提交的文件，包括我们 10-K 表格和 10-Q 表格中 “风险因素” 和 “管理层对财务状况和经营成果的讨论与分析” 下的讨论。我们没有义务公开更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，法律要求的情况除外。</p>
</div><p><em>Oura Ring is not a medical device and is not intended to diagnose, treat, cure, monitor, or prevent medical conditions or illnesses.</em></p>
<div class="lb-trans"><p>Oura Ring 不是医疗设备，不用于诊断、治疗、治愈、监测或预防医疗状况或疾病。</p>
</div><table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1Burch RC, Buse DC, Lipton RB. Migraine: Epidemiology, Burden, and Comorbidity. Neurol Clin. 2019 Nov;37(4):631-649. doi: 10.1016/j.ncl.2019.06.001. Epub 2019 Aug 27. PMID: 31563224.</td>
</tr>
<tr>
<td>2 https://www.who.int/news-room/fact-sheets/detail/headache-disorders</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1Burch RC, Buse DC, Lipton RB. 偏头痛：流行病学、负担和共病。神经病学临床。2019 年 11 月；37(4)：631-649。doi: 10.1016/j.ncl.2019.06.001。2019 年 8 月 27 日在线发表。PMID: 31563224.</td>
</tr>
<tr>
<td>2 https://www.who.int/news-room/fact-sheets/detail/headache-disorders</td>
</tr>
</tbody>
</table>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAxMDYyNjM4MThyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260106263818r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20260106263818/en/</p>
<div class="lb-trans"><p>查看在 businesswire.com 上的源版本：https://www.businesswire.com/news/home/20260106263818/en/</p>
</div><p><strong>Aptar Investors Relations Contact:</strong></p>
<div class="lb-trans"><p><strong>Aptar 投资者关系联系人：</strong></p>
</div><p>Mary Skafidas</p>
<div class="lb-trans"><p>Mary Skafidas</p>
</div><p>mary.skafidas@aptar.com</p>
<div class="lb-trans"><p>mary.skafidas@aptar.com</p>
</div><p>+1 347 351 6407</p>
<div class="lb-trans"><p>+1 347 351 6407</p>
</div><p><strong>Aptar Pharma Media Contact:</strong></p>
<div class="lb-trans"><p><strong>Aptar 制药媒体联系人：</strong></p>
</div><p>Carolyn Penot</p>
<div class="lb-trans"><p>Carolyn Penot</p>
</div><p>carolyn.penot@aptar.com</p>
<div class="lb-trans"><p>carolyn.penot@aptar.com</p>
</div><p>+33 6 37 36 76 84</p>
<div class="lb-trans"><p>+33 6 37 36 76 84</p>
</div><p><strong>Aptar Media Contact:</strong></p>
<div class="lb-trans"><p><strong>Aptar 媒体联系人：</strong></p>
</div><p>Katie Reardon</p>
<div class="lb-trans"><p>Katie Reardon</p>
</div><p>katie.reardon@aptar.com</p>
<div class="lb-trans"><p>katie.reardon@aptar.com</p>
</div><p>+1 815 479 5671</p>
<div class="lb-trans"><p>+1 815 479 5671</p>
</div><p>Source: AptarGroup, Inc.</p>
<div class="lb-trans"><p>来源：AptarGroup, Inc.</p>
</div>

阿普达数字健康与ŌURA 合作，通过将 Migraine Buddy®与 Oura Ring 连接来提升对偏头痛的洞察 | ATR 股票新闻